Listed by the USPTO as WEHBE, ANNE MARIE SABRINA
Tech Center 1600 • Art Units: 1631 1633 1634 1656
This examiner grants 57% of resolved cases
Anne Marie Sabrina Wehbe has 705 resolved cases in Art Unit 1631. The allowance rate for these matters is 57.3%. The median days to allowance is 1334. This 1334-day timeline provides a benchmark for applicants to anticipate the duration of successful prosecution. The 57.3% allowance rate reflects the historical frequency of grants among resolved cases in Tech Center 1600.
The data includes an interview lift of 43.3%. This 43.3% metric indicates that conducting an interview is associated with a much higher probability of allowance compared to cases without one. Top companies on this docket include Massachusetts Institute of Technology, Regeneron Pharmaceuticals Inc., and Cedars-Sinai Medical Center. The 43.3% lift suggests that oral advocacy is a highly productive strategy.
Firms such as Johnson, Marcou, Isaacs & Nix, LLC, BAKER BOTTS L.L.P., and ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP frequently represent clients. The 1334-day median pendency is a key factor for managing client expectations. With 705 resolved cases, these statistics offer a data-grounded view of prosecution trends.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | Non-Final OA | Nant Holdings IP, LLC |
| 19390128 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Final Rejection | Massachusetts Institute of Technology |
| 17707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17642541 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18351246 | Macrophage Cell Therapy to Treat Orthopedic Injury | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18516366 | PROTEIN PROSTHESES FOR MITOCHONDRIAL DISEASES OR CONDITIONS | Final Rejection | The General Hospital Corporation |
| 18999448 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17579185 | RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19312145 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18260305 | MODULAR KINETICALLY-CONTROLLED FUNCTIONAL RNA CONSTRUCTS AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 18259088 | Tightly-Regulated Inducible Expression System for Production of Biologics Using Stable Cell Lines | Non-Final OA | National Research Council of Canada |
| 18740824 | NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME | Non-Final OA | Baylor College of Medicine |
| 17767803 | VARIANT IGF2 CONSTRUCTS | Final Rejection | Amicus Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.3% of resolved applications examined by Anne Marie Sabrina Wehbe were allowed (705 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +43.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Anne Marie Sabrina Wehbe took 1,334 days on average from filing to allowance.
Anne Marie Sabrina Wehbe examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
